Durable Responses in Patients With Advanced Cholangiocarcinoma on Sequential Dual-agent Immunotherapy After Progressing on Single-agent Immunotherapy.

Kaakour, Dalia; Hagopian, Garo; Lee, Sonia; Lee, Fa Chyi

Kaakour, Dalia; Hagopian, Garo; Lee, Sonia; Lee, Fa Chyi.

Afiliación

Kaakour D; Department of Medicine.
Hagopian G; Department of Medicine.
Lee S; Department of Radiological Sciences.
Lee FC; Division of Hematology/Oncology, Department of Medicine, University of California Irvine. Irvine, CA.

Am J Clin Oncol ; 45(10): 410-414, 2022 10 01.

Article en En | MEDLINE | ID: mdl-36102355

Asunto(s)

Colangiocarcinoma; Nivolumab; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Colangiocarcinoma/tratamiento farmacológico; Humanos; Factores Inmunológicos; Inmunoterapia; Ipilimumab; Inestabilidad de Microsatélites; Nivolumab/uso terapéutico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Colangiocarcinoma / Nivolumab Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Am J Clin Oncol Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google